非小细胞肺癌血清VEGF、bFGF和TNF-α的临床意义  

The Clinical Significance of Serum VEGF,bFGF and TNF-α in Non-small Cell Lung Cancer

作　　者：李英[1] 董良[1] 李海金[1] 尚官敏[1] 陈亚男[1] 葛丽娜[1] 王伟英[1] 赵建刚[1] 

机构地区：[1]中国医科大学绍兴医院,浙江绍兴312030

出　　处：《肿瘤学杂志》2013年第1期50-54,共5页Journal of Chinese Oncology

基　　金：浙江省医学会临床科研基金项目(2009ZYC43)

摘　　要：[目的]观察非小细胞肺癌(NSCLC)患者血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)和肿瘤坏死因子α(TNF-α)与NSCLC临床特征的相关性,探讨三者在NSCLC疗效评价中的临床价值。[方法]采用双抗体夹心酶联免疫吸附法(ELISA)检测NSCLC患者化疗前1d、化疗结束1周后血清VEGF、bFGF和TNF-α的含量。[结果]NSCLC患者化疗前血清VEGF、bFGF和TNF-α与患者临床分期有关(P<0.05),与患者年龄、性别及病理类型无关;分析68例晚期NSCLC患者化疗前后血清VEGF、bFGF和TNF-α的变化,临床获益组与疾病进展组比较三者均有明显下降(P<0.05)。[结论]血清VEGF、bFGF和TNF-α与NSCLC肿瘤负荷有关;血清VEGF、bFGF和TNF-α水平可作为NSCLC患者化疗疗效预测的参考指标。[Purpose] To investigate the levels of serous vascular endothelial growth factor （VEGF）,basic fibroblast growth factor （bFGF）,and tumor necrosis factor-α （TNF-α） in patients with non-small cell lung cancer（NSCLC） and their relationships with clinical characteristics,and their clinical significance in the evaluation of treatment outcomes were studied. [Methods] The levels of serous VEGF,bFGF and TNF-α were detected by enzyme-linked immunosorbent assay （ELISA） in NSCLC patients before chemotherapy and one week after chemotherapy. [Results] Serous VEGF,bFGF and TNF-α before chemotherapy were correlated with clinical stage （P 0.05）,but not with age,gender and pathological type. Among 68 patients with advance NSCLC, the levels of serous VEGF,bFGF and TNF-α declined significantly after chemotherapy in clinical benefit patients than those in patients with progressive disease （PD） （P0.05）. [Conclusion] Serous VEGF,bFGF and TNF-α are related to the cancer load in NSCLC patients. Serous VEGF,bFGF and TNF-α might be helpful in predicting of chemotherapeutic response.

关 键 词：癌 非小细胞肺 血管内皮生长因子 碱性成纤维细胞生长因子 肿瘤坏死因子Α 

分 类 号：R734.2[医药卫生—肿瘤]